Castle Biosciences to Present at the 23rd Annual Needham Virtual Growth Conference

Rhea-AI Summary

Castle Biosciences, Inc. (Nasdaq: CSTL) announced that Derek Maetzold, CEO, will present a company overview at the 23rd Annual Needham Virtual Growth Conference on January 15, 2021, at 11:30 a.m. Eastern time. A live audio webcast of the presentation will be accessible on Castle Biosciences’ website, with a replay available for two weeks post-event. The company specializes in providing personalized genomic information to enhance cancer treatment decisions, offering tests for various skin cancers including melanoma and squamous cell carcinoma.

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the 23rd Annual Needham Virtual Growth Conference on Jan. 15, 2021, at 11:30 a.m. Eastern time.

A live audio webcast of the company’s presentation will be available by visiting Castle Biosciences’ website at https://ir.castlebiosciences.com/news-events/events-presentations. A replay of the webcast will be available for two weeks following the conclusion of the live broadcast.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx^®-Melanoma, DecisionDx^®-CMSeq), cutaneous squamous cell carcinoma (DecisionDx^®-SCC), suspicious pigmented lesions (DecisionDx^® DiffDx™-Melanoma) and uveal melanoma (DecisionDx^®-UM, DecisionDx^®-PRAME and DecisionDx^®-UMSeq). For more information about Castle’s gene expression profile tests, visit www.CastleTestInfo.com. Castle also has active research and development programs for tests in other dermatologic diseases with high clinical need. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona. For more information, visit www.CastleBiosciences.com.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq and are trademarks of Castle Biosciences, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210104005012/en/

FAQ

When is Castle Biosciences' presentation at the Needham Virtual Growth Conference?

Castle Biosciences will present on January 15, 2021, at 11:30 a.m. Eastern time.

Where can I watch the Castle Biosciences conference presentation?

You can watch the live audio webcast on Castle Biosciences’ website during the presentation.

What is the focus of Castle Biosciences?

Castle Biosciences focuses on providing personalized genomic information for skin cancer treatment decisions.

What types of tests does Castle Biosciences offer?

Castle Biosciences offers tests for cutaneous melanoma, cutaneous squamous cell carcinoma, and uveal melanoma, among others.

How long will the webcast replay be available after the live presentation?

The replay of the webcast will be available for two weeks following the live broadcast.